💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, trading cheap versus its own history.
Abbott India is scored on the pharma / healthcare framework. It keeps a fat 21.5% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.85×). Free cash flow is worth about 1.7% of its market value.
Over the last 3 years revenue compounded at 10%/yr and profit at 18%/yr. Book value has grown 14%/yr. Return on equity is an elite 37.9%. In the latest quarter profit grew 9% versus the prior quarter.
At 36× earnings, the stock sits at the 10th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~16%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 34.66 | — | — |
| P/B | 11.72 | 4.11 | worse |
| EV/EBITDA | 23.44 | 19.15 | worse |
| ROE | 37.86 | — | — |
| ROCE | 54.9 | — | — |
| ROA | 33.03 | — | — |
| Quick Ratio | 1.91 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 9% CAGR — growing but slowly.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (18% vs 9%) — margin expansion is at work.
Operating margin has expanded from 23% to 29% — the business is keeping more of each rupee earned.
ROE at 33% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 18% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 6% sequentially — momentum is building. Low quarterly variance (6% spread) — a predictable, non-seasonal revenue stream.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 75.0% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.